2026 VB100: China's Top 50 Most Innovative Medical Health Products & Technologies

Policy support, technological iteration, and upgrading demand—these three driving forces are jointly propelling China’s healthcare industry into a golden period of development. A wave of products featuring China-first launches and global first-in-class innovations is emerging in volume. Domestic substitution is advancing deeper into core areas, while frontier fields such as AI, brain-computer interfaces, and cell and gene therapy are accelerating their clinical and commercial deployment. Chinese medical innovation stands at a critical tipping point, transitioning from technological breakthroughs to scaled, global application.

Against this backdrop, VCBeat has launched initiatives anchored in its core mission of “showcasing, trading, and empowering China’s healthcare innovation assets.”“Top 50 Most Innovative Products and Technologies in China’s Healthcare Industry”, to discover breakthrough products and technologies that represent the pinnacle of China’s original innovation and possess global competitiveness, with higher standards and a broader perspective, comprehensively showcasing the historic leap of China’s medical innovation from “technological following” to “exporting original resources.”

The fundamental shift in evaluation logic reflects the leap in China’s position as a primary driver of medical innovation.

In the early years, domestically developed innovative products were rare exceptions, and “first-in-China” launches were merely niche labels. Today, however, a wave of such first-in-China innovations is emerging in volume, not only precisely addressing unmet clinical needs but also becoming a core force in global competition. Consequently, the criteria for this year’s awards have shifted from focusing solely on technological innovation to emphasizing both the “scarcity of China-first innovations” and the “competitiveness of global breakthroughs.”

Centered on this dual value, the selection process has established a four-dimensional evaluation framework comprising “Originality–Clinical Value–Global Potential–Commercialization Prospects,” and adheres to three core orientations, each corresponding to specific review criteria:

Strengthening First-in-Class and First-in-World Innovations: The evaluation focuses on whether the product demonstrates significant advantages over similar products in terms of applied technology, resolution of clinical needs, therapeutic efficacy, or process efficiency, or achieves original breakthroughs at the levels of concept, technology, product, platform, and service. Whether it involves innovative targets and mechanisms in biotechnology, new algorithms and platforms in digital technology, or new design concepts and functional implementations in intelligent medical devices, “China’s first launch and first creation” serves as the key benchmark.

Focusing on Global Value: Extending from domestic clinical value to global market competitiveness. Candidate products must demonstrate clear unmet clinical needs and internationalization potential; for instance, biotechnology products should have completed or be undergoing clinical trials, digital health products should have completed technical validation and user testing, and intelligent medical devices should possess proven value in clinical applications. The evaluation particularly focuses on whether products can secure a position in the global healthcare landscape, thereby accelerating the overseas expansion of Chinese innovations.

Anchoring on Clinical Efficacy and Commercial Viability: Balancing technological breakthroughs, clinical efficacy, and commercial viability. Eligible products must be free from negative reports concerning patent disputes, data fabrication, academic misconduct, technology infringement, or privacy breaches, and must demonstrate clear market application prospects and a defined commercialization pathway. Biotechnology and intelligent medical device products should be poised for scaled production and sales, while digital technology products should be ready for large-scale deployment and application. This initiative aims to drive innovation from the laboratory to the marketplace, transforming prototypes into tradable, value-enabling assets.

The Top 50 Most Innovative Product Technologies of the Year serve as a concentrated validation of the aforementioned selection criteria.

Smart Medical Device Sectorhigh-end imaging, surgical robots, neuromodulation and other products have achieved independent control of core components, with multiple achievements reaching a global leading level;Digital Technology Sectorlarge medical AI models and digital therapeutics are deeply integrated throughout the entire process, restructuring service efficiency through data algorithms;Biotechnology SectorRapid iteration in innovative drugs, cell therapy, and gene editing has led to the continuous emergence of locally developed original novel targets and mechanisms, significantly enhancing global competitiveness.

This cohort of products, spanning three high-growth sectors and achieving key breakthroughs in technical principles, clinical value, or commercialization models, is enabling Chinese medical innovation to truly go global—transitioning from “storytelling” to “value creation.”

【Top 50 Most Innovative Products and Technologies in China’s Healthcare Industry 2026】has been2026 Future Healthcare 100 Awards CeremonyAnnounced on-site, the strategic partner for this awards ceremony isHSBC Sci-Tech Innovation Finance。